Aurobindo Pharma's subsidiary Acrotech Biopharma has acquired portfolio Outlook & Valuations: On valuation front, the company paid almost 1.6xMarketCap/sales (on upfront payment), which we believe is very attractive. The addition whole US$140mn will be paid up if the sales for the two said above products reach US$800mn; which we believe is attractive. On the Operating